This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE)/BioNTech Give First COVID Jab Booster Data to FDA
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) booster dose of COVID-19 vaccine elicited antibody levels that were much higher than that seen after the two-dose primary schedule.
Company News for Aug 17, 2021
by Zacks Equity Research
Companies in The News are: NIU,SA,PFE,BNTX,TSLA
Pfizer's (PFE) Tick-Borne Encephalitis Vaccine Gets FDA Nod
by Zacks Equity Research
Pfizer's (PFE) tick-borne encephalitis vaccine that is already approved in Europe and other countries gains FDA approval.
Moderna (MRNA) Gets EUA for Third Dose of COVID-19 Vaccine
by Zacks Equity Research
The FDA authorizes third dose of Moderna's (MRNA) COVID-19 vaccine for use in immunocompromised adults.
Moderna ETFs to Shine Bright on Booster Update, New Study Data
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.
Pharma Stock Roundup: FDA Nod for SNY's Pompe Drug & New Use of MRK's Keytruda
by Kinjel Shah
FDA approves Sanofi's (SNY) Nexviazyme for late-onset Pompe disease and Merck's (MRK) Keytruda plus Lenvima for first-line kidney cancer.
Merck's (MRK) Keytruda/Lenvima Get FDA Nod for Kidney Cancer
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda + partenr Eisai's Lenvima for advanced RCC in the first-line setting based on data from the phase III CLEAR/KEYNOTE-581 study.
mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally
by Indrajit Bandyopadhyay
Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.
Merck's (MRK) Two Keytruda sBLAs Get Accepted by the FDA
by Zacks Equity Research
FDA likely to decide on Merck's (MRK) sBLA for Keytruda as an adjuvant therapy in certain patients with RCC on Dec 10 and in certain patients with MSI-H/dMMR advanced endometrial carcinoma on Mar 28, 2022.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates
by Kinjel Shah
Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce Q2 results. FDA approves AstraZeneca's (AZN) lupus medicine, Saphnelo. Sanofi (SNY) to buy Translate Bio.
Aerie's(AERI) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) incurs wider-than-expected loss in the second quarter of 2021 but sales beat expectations.
BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.
Top Research Reports for Amazon, Pfizer & Verizon
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Pfizer Inc. (PFE), and Verizon Communications Inc. (VZ).
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.
Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Pharma & Healthcare ETFs at a One-Year High: Here's Why
by Sanghamitra Saha
Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
Stock Market News for Jul 29, 2021
by Zacks Equity Research
U.S. stock markets closed mixed on Wednesday following the Fed's decision to keep interest rate near zero.
Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Trade Numbers Sink Near Record, Q2 Earnings Beats for PFE, BA & MCD
by Mark Vickery
Boeing (BA) posted a surprise profit in Q2, and shares are up over 5% in pre-market trading as a result.
Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.